Elsevier

European Journal of Cancer

Volume 28, Issues 2–3, February–March 1992, Pages 667-672
European Journal of Cancer

Breast Cancer Working Conference, 3–6 September 1991, Leuven
Systemic treatment for locally advanced breast cancer: What we still need to learn after a decade of multimodality clinical trials

https://doi.org/10.1016/S0959-8049(05)80122-4Get rights and content

Multimodality therapy of locally advanced breast cancer with initial chemo-(hormono)-therapy followed by locoregional treatment has become increasingly popular during the past decade. A paucity of large randomised clinical trials leaves the following unanswered questions: does systemic treatment impact on long-term control of distant metastases? What is the best treatment sequence? The most effective drug combination? The optimum treatment duration? Future prospects in the treatment of locally advanced breast cancer include the use of haematopoietic growth factors to increase the dose-intensity of neoadjuvant chemotherapy, the investigation of autologous bone marrow transplantation with high dose chemotherapy on a larger scale, the development of new approaches designed at interrupting the “autocrine loop” of breast cancer local growth factors and the introduction of diphosphonates in the adjuvant systemic therapy.

References (50)

  • PetoR

    Why do we need systematic overviews of randomized trials?

    Stat Med

    (1987)
  • Schaarke-KoningC et al.

    Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study

    Int J Radiat Oncol Biol Phys

    (1985)
  • KlefstromP et al.

    Adjuvant post-operative radiotherapy, chemotherapy and immunotherapy

    Cancer

    (1987)
  • SponzoR et al.

    The management of non-resectable (stage III) breast cancer

  • PiccartMJ et al.

    Six-year results of a multimodality treatment strategy for locally advanced breast cancer

    Cancer

    (1988)
  • MeekAG et al.

    Concurrent radiochemotherapy in advanced breast cancer

    Cancer

    (1983)
  • DelenaM et al.

    Combined chemotherapy — radiotherapy approach in locally advanced (T3b-T4) breast cancer

    Cancer Chemother Pharmacol

    (1978)
  • ValagussaP et al.

    Prognostic factors in locally advanced inflammatory breast cancer — long-term results following primary chemotherapy

    Breast Cancer Res Treat

    (1990)
  • HortobagyiG et al.

    Comparison of two adjuvant chemotherapy programs for locally advanced breast cancer: a prospective randomized trial

  • CoconiG et al.

    Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma

    Am J Clin Oncol

    (1990)
  • AlagaratmanTT et al.

    Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer

    Aust NZ J Surg

    (1986)
  • KeilingR et al.

    Preoperative chemotherapy in the treatment of inflammatory breast cancer

  • SoraceRA et al.

    The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery

    World J Surg

    (1985)
  • LippmanME et al.

    Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer

  • ContePF et al.

    Chemotherapy with estrogenic recruitment in locally advanced and metastatic breast cancer: results of two randomized trials

  • Cited by (17)

    • Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: Final results of a prospective phase II study

      2014, Breast
      Citation Excerpt :

      Primary systemic treatment is the standard for management of stage IIA-IIB/IIIA breast cancer. Primary aim is the achievement of a pCR, which is correlated to a better 10-year OS and DFS and a lower risk of recurrences [3–5]. A wide variety of chemotherapy regimens have been used as preoperative treatment, with most incorporating doxorubicin.

    • Selective Mastectomy in the Management of Locally Advanced Breast Cancer

      2007, International Journal of Radiation Oncology Biology Physics
      Citation Excerpt :

      Local disease was most likely to be symptomatic at death when the primary tumor was ≥10 cm. Induction chemotherapy (and less often hormonal therapy) is now the standard of care in the management of LABC (33–38). Initial systemic therapy is a means of rendering a patient operable (35), as well as dealing with micrometastatic disease as soon as possible.

    • Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx®) and paclitaxel in locally advanced breast cancer: A phase II study by the Hellenic Cooperative Oncology Group

      2002, Annals of Oncology
      Citation Excerpt :

      A wide variety of chemotherapy regimens have been used as preoperative treatment, with most incorporating doxorubicin. These regimens generally produce a response rate in at least two-thirds of patients with a complete pathological remission rate of approximately 10–15% [1]. Anthracyclines such as doxorubicin are considered among the most active single agents in advanced breast cancer.

    • Primary chemotherapy in breast cancer

      1998, Biomedicine and Pharmacotherapy
    View all citing articles on Scopus
    View full text